Breast Cancer Treatment Market Report and Forecast 2023-2031

The global breast cancer treatment market is expected to grow significantly during the forecast period of 2023-2031. The market is driven by the increasing incidence of breast cancer across the globe and the growing demand for advanced treatment options. The market was valued at USD 20.64 billion in 2022. The market is expected to grow at a CAGR of 10.01% during the forecast period to reach USD 49.08 billion by 2031.

Breast Cancer Treatment Market: Introduction

Breast cancer is one of the most common types of cancer, affecting millions of people worldwide. The increasing prevalence of breast cancer, especially among women, is a major factor driving the growth of the breast cancer treatment market. The market is highly competitive, with key players focusing on research and development activities to develop innovative products and strengthen their market position.

Breast Cancer - Epidemiology

Breast cancer is one of the most common types of cancer worldwide. According to the World Health Organization (WHO), breast cancer is the most common cancer among women, accounting for approximately 30% of all newly diagnosed cancers in women globally. In 2020, there were an estimated 2.3 million new cases of breast cancer diagnosed worldwide, making it the second most common cancer overall, after lung cancer.

The incidence of breast cancer varies by region, with higher rates observed in developed countries. In North America, breast cancer is the most commonly diagnosed cancer among women, with an estimated 281,550 new cases expected in 2021, according to the American Cancer Society. In Europe, breast cancer is also the most common cancer among women, with an estimated 562,500 new cases in 2020, according to the International Agency for Research on Cancer (IARC).

The incidence of breast cancer is also increasing in many low- and middle-income countries. According to the WHO, breast cancer incidence has been steadily increasing in Africa, Asia, and Latin America over the past few decades, due in part to changing lifestyles, including increased urbanization and adoption of Western-style diets and reproductive patterns. Additionally, breast cancer is often diagnosed at a later stage in these countries, leading to poorer outcomes.

Breast cancer incidence is also influenced by several risk factors, including age, family history of breast cancer, reproductive factors, hormonal factors, lifestyle factors (such as physical inactivity and alcohol consumption), and exposure to radiation or certain chemicals. Early detection through screening and prompt treatment are crucial for improving breast cancer outcomes.

Breast Cancer Treatment Market Segmentations

The market can be categorised into diagnosis, therapy, indication, distribution channel, and region.

Market Breakup by Diagnosis

• Imaging
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Market Breakup by Therapy

Targeted Therapy

• Abemaciclib
• Ado-Trastuzumab Emtansine
• Everolimus
• Trastuzumab
• Ribociclib
• Palbociclib
• Pertuzumab
• Olaparib
• Others

Hormonal Therapy

• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Estrogen Receptor Downregulators (ERDs)
• Chemotherapy
• Immunotherapy
• Others

Breast Cancer Treatment Market Breakup by Indication

• Invasive Ductal Carcinoma
• Invasive Lobular Carcinoma
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Breast Cancer Treatment Market Scenario

The global breast cancer treatment market is expected to grow significantly during the forecast period of 2023-2031, driven by factors such as the increasing incidence of breast cancer, growing demand for advanced treatment options, and the availability of advanced healthcare infrastructure in developed countries.

North America dominates the breast cancer treatment market, followed by Europe and the Asia Pacific. The market in North America is driven by factors such as the high incidence of breast cancer, well-established healthcare infrastructure, and the availability of advanced diagnostic and treatment options. The market in Europe is also expected to grow significantly, with key players focusing on research and development activities to develop innovative products. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about breast cancer and the rising healthcare expenditure in the region.

Key Players in the Global Breast Cancer Treatment Market

The report gives an in-depth analysis of the key players involved in the breast cancer treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Mylan N.V (Viatris Inc.)
• AstraZeneca
• Celltrion Inc
• Bristol-Myers Squibb Company
• Fresenius Kabi AG
• Eisai Co., Ltd
• Baxter
• GSK plc
• Pfizer Inc
• Halozyme, Inc
• Novartis AG